A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
- PMID: 28249076
- DOI: 10.1001/jamapsychiatry.2017.0080
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Abstract
Importance: Several studies now provide evidence of ketamine hydrochloride's ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment. Despite the relatively small sample sizes, lack of longer-term data on efficacy, and limited data on safety provided by these studies, they have led to increased use of ketamine as an off-label treatment for mood and other psychiatric disorders.
Observations: This review and consensus statement provides a general overview of the data on the use of ketamine for the treatment of mood disorders and highlights the limitations of the existing knowledge. While ketamine may be beneficial to some patients with mood disorders, it is important to consider the limitations of the available data and the potential risk associated with the drug when considering the treatment option.
Conclusions and relevance: The suggestions provided are intended to facilitate clinical decision making and encourage an evidence-based approach to using ketamine in the treatment of psychiatric disorders considering the limited information that is currently available. This article provides information on potentially important issues related to the off-label treatment approach that should be considered to help ensure patient safety.
Comment in
-
Use of Ketamine in Clinical Practice: A Time for Optimism and Caution.JAMA Psychiatry. 2017 Apr 1;74(4):405-406. doi: 10.1001/jamapsychiatry.2017.0078. JAMA Psychiatry. 2017. PMID: 28249064 No abstract available.
-
Ketamine for the Treatment of Depression-Reply.JAMA Psychiatry. 2017 Sep 1;74(9):971-972. doi: 10.1001/jamapsychiatry.2017.1776. JAMA Psychiatry. 2017. PMID: 28700772 No abstract available.
-
Ketamine for the Treatment of Depression.JAMA Psychiatry. 2017 Sep 1;74(9):971. doi: 10.1001/jamapsychiatry.2017.1779. JAMA Psychiatry. 2017. PMID: 28700777 No abstract available.
-
Ketamine for the Treatment of Depression.JAMA Psychiatry. 2017 Sep 1;74(9):970-971. doi: 10.1001/jamapsychiatry.2017.1773. JAMA Psychiatry. 2017. PMID: 28700782 No abstract available.
-
Ketamine for the Treatment of Depression.JAMA Psychiatry. 2017 Sep 1;74(9):970. doi: 10.1001/jamapsychiatry.2017.1770. JAMA Psychiatry. 2017. PMID: 28700802 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical